VISION Trial Summary: Lutetium 177 PSMA 617 for Metastatic Prostate Cancer
2021 VISION TRIAL Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer Prospective, open-label, randomized, international, phase 3 trial Objective: To evaluate Lutetium-177 (177Lu)-PSMA-617 a radioligand therapy along...